NCT00223743View on ClinicalTrials.gov

A Safety/Efficacy Trial of Zonisamide for Essential Tremor

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

September 30, 2008

Conditions
Essential Tremor
Interventions
DRUG

Zonisamide

study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.

Trial Locations (1)

90073

VA Greater Los Angeles, Los Angeles

All Listed Sponsors
collaborator

Ralph M. Parsons Foundation

OTHER

lead

VA Greater Los Angeles Healthcare System

FED

NCT00223743 - A Safety/Efficacy Trial of Zonisamide for Essential Tremor | Biotech Hunter | Biotech Hunter